← Back to Previous Page

 

P273: A CASE SERIES OF 11 PITUICYTOMAS OUTCOMES BY SUBTYPE
Jack D Sedwick III, BA¹; Kyle Montgomery, BS¹; Rya W Berrigan, BS¹; Christopher Seward, MD²; Eric D Lassiter, BS¹; Tyler Lazaro, MD²; Thomas Hanks, BS¹; Dominic Nistal, MD²; Manuel Ferreira Jr, MD, PhD²; Samuel Emerson, MD, PhD²; Jacob Ruzevick, MD²; ¹University of Washington School of Medicine; ²University of Washington Department of Neurological Surgery

Introduction: Pituicytomas are rare, low-grade neoplasms that arise from glial cells of the neurohypophysis, known as pituicytes. The 2021 WHO classification divided pituicytomas into four subtypes based on ultrastructural characteristics: pituicytoma, granular cell, oncocytic and ependymal. There is a dearth of data regarding the outcomes of pituicytoma and their subtypes. We present a single-center case series of 11 pituicytomas.

Methods: A single-center retrospective chart review of surgeries from 2001-2025 was performed. All patients were screened for pathologically confirmed pituicytoma. Demographics, presenting symptoms, surgical approach, postoperative complications, outcomes, and progression free survival were reviewed. Pituicytoma analysis was separated by subtype.

Results: A cohort of 11 symptomatic pituicytomas underwent surgical resection, 8 via transsphenoidal surgery and 3 via craniotomy. Five patients achieved gross total resection (GTR) and 6 patients subtotal resection. Six patients required at least one hormone replacement postoperatively. Six patients were able to be followed for long-term outcomes with an average 26.1 (±27.3) months and no patients experienced recurrence defined as radiologic progression. The case series data is summarized in Table 1.

Discussion: In our cohort, there was no recurrence after GTR or subtotal resection suggesting surgery is effective at mitigating long-term recurrence. Half of the patients required hormone replacement postoperatively. There were no other complications.

Table 1: Preliminary Results for Patients with Pituicytoma

Variable	N
Male	5 (45%)
Average Age at presentation (SD)	58.3 (±11.8)
Visual Distrubance at presentation	7 (64%)
Hormal Dysfunction at presentation	10 (91%)
Surgical Approach ETSS Craniotomy	8 (73%) 3 (27%)
Resection Status GTR STR	5 6
Tumor Type Pituicytoma Spindle Cell Oncocytoma Granular Cell Tumor Ependymal Pituicytoma	4 2 4 1
Post Operative Complications Visual Disturbance Hypopituitary	0 6
PFS in Months	26.2 (±27.3)
Recurrence	0

View Poster

 

← Back to Previous Page